Transient asymptomatic pulmonary opacities in a patient with MET exon 14 skipping non-small cell lung cancer: A case report

被引：1
作者：
Ikeo, Satoshi [1 ,2 ,3 ]
Yasuda, Naoaki [1 ]
Sakai, Yuki [1 ]
Hayashi, Yasuyuki [1 ]
Sokai, Akihiko [1 ]
Iwata, Toshiyuki [1 ]
Nishimura, Takashi [1 ]
机构：
[1] Kyoto Katsura Hosp, Dept Resp Med, Kyoto, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Resp Med, Kyoto, Japan
[3] Kyoto Katsura Hosp, Dept Resp Med, 17 Yamadahiraocho,Nishikyo Ku, Kyoto 6158256, Japan
来源：
THORACIC CANCER | 2023年 / 14卷 / 10期
基金：
日本学术振兴会;
关键词：
lung cancer; MET exon 14 skipping; tepotinib; transient asymptomatic pulmonary opacities; OSIMERTINIB; AMPLIFICATION; MUTATIONS;
D O I：
10.1111/1759-7714.14831
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Mesenchymal epithelial transition factor receptor (MET) tyrosine kinase inhibitors (MET-TKIs) have been approved for the treatment of non-small cell lung cancers with MET exon 14 skipping mutations. Transient asymptomatic pulmonary opacities (TAPOs) associated with epidermal growth factor receptor (EGFR)-TKIs have been reported. Here, we report a case wherein ground-glass opacities (GGOs) appeared during the course of treatment with tepotinib, a MET-TKI, but spontaneously resolved with drug withdrawal, after which treatment was resumed with a reduced dose. Although there have been no reports of TAPOs with MET-TKIs, the clinical and imaging findings of this case were consistent with TAPOs. For TAPOs occurring because of MET-TKI, the drug can be continued under careful observation even if GGOs appear.
引用
收藏
页码：958 / 960
页数：3
相关论文
共 14 条
  • [1] Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision
    Ahn, Myung-Ju
    Sun, Jong-Mu
    Lee, Se-Noon
    Ahn, Jin Seok
    Park, Keunchil
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (12) : 2051 - 2052
  • [2] Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis
    Awad, Mark M.
    Leonardi, Giulia C.
    Kravets, Sasha
    Dahlberg, Suzanne E.
    Drilon, Alexander
    Noonan, Sinead A.
    Camidge, D. Ross
    Ou, Sai-Hong, I
    Costa, Daniel B.
    Gadgeel, Shirish M.
    Steuer, Conor E.
    Forde, Patrick M.
    Zhu, Viola W.
    Fukuda, Yoko
    Clark, Jeffrey W.
    Janne, Pasi A.
    Mok, Tony
    Sholl, Lynette M.
    Heist, Rebecca S.
    [J]. LUNG CANCER, 2019, 133 : 96 - 102
  • [3] MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
    Awad, Mark M.
    Oxnard, Geoffrey R.
    Jackman, David M.
    Savukoski, Daniel O.
    Hall, Dimity
    Shivdasani, Priyanka
    Heng, Jennifer C.
    Dahlberg, Suzanne E.
    Anne, Pasi A. J.
    Verma, Suman
    Christensen, James
    Hammerman, Peter S.
    Sholl, Lynette M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07) : 721 - +
  • [4] Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review
    Cortot, Alexis
    Le, Xiuning
    Smit, Egbert
    Viteri, Santiago
    Kato, Terufumi
    Sakai, Hiroshi
    Park, Keunchil
    Camidge, D. Ross
    Berghoff, Karin
    Vlassak, Soetkin
    Paik, Paul K.
    [J]. CLINICAL LUNG CANCER, 2022, 23 (03) : 195 - 207
  • [5] Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report
    Hashiguchi, Mizuha Haraguchi
    Sato, Takashi
    Yamamoto, Hiroki
    Watanabe, Rinako
    Kagyo, Junko
    Domoto, Hideharu
    Shiomi, Tetsuya
    [J]. JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (02):
  • [6] Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review
    Itano, Junko
    Higo, Hisao
    Ohashi, Kadoaki
    Makimoto, Go
    Nishii, Kazuya
    Hotta, Katsuyuki
    Miyahara, Nobuaki
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    [J]. INTERNAL MEDICINE, 2020, 59 (06) : 823 - 828
  • [7] Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication
    Lee, Hansang
    Lee, Ho Yun
    Sun, Jong-Mu
    Lee, Se-Noon
    Kim, Youjin
    Park, Song Ee
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : 1106 - 1112
  • [8] Miyauchi Eisaku, 2017, J Thorac Oncol, V12, pe59, DOI 10.1016/j.jtho.2017.01.027
  • [9] Retreatment With Osimertinib Following Pneumonitis
    Nagasaka, Misako
    Gadgeel, Shirish M.
    [J]. CLINICAL LUNG CANCER, 2018, 19 (01) : E53 - E55
  • [10] Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib Treatment
    Noonan, Sinead A.
    Sachs, Peter B.
    Camidge, D. Ross
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (12) : 2253 - 2258
12